SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Theravance - THRX
THRX 9.810+0.4%Jan 8 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kenhott who wrote (32)8/23/2006 11:07:08 AM
From: rkrw   of 74
 
A big selling point for cubicin is it's once daily (same as telavancin), so it's amenable to outpatient use. They also have the bacteremia data thrx doesn't have, which also showed a fairly similar to standard of care outcomes.

I think they'll be a market for all the drugs. Cubicin is on track for roughly $200M in sales this year and they're projecting at least $500M at peak.

Hospital acquired pneumonia data will be important for thrx, due out sometime next year. Cubicin failed that indication as it doesn't get into the lungs very well whereas telavancin does.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News